Saturday, November 25, 2017

Medicines Shortages - European Commission eCOST Research Network - Action CA15105


eCOST (European Cooperation in Science and Technology) is the longest-running European framework supporting trans-national cooperation among researchers, engineers and scholars across Europe.

European Medicines Shortages Research Network - addressing supply problems to patients (Medicines Shortages) 

The problems created by supply shortages of medicines have been widely reported by healthcare professionals and patients over recent years, and acknowledged at the European level by the European Medicines Agency and European Commission. The cited causes are multifaceted ranging from production disruptions, natural disasters, discontinuations as well as difficulties created by various legal, trade and pricing frameworks. Healthcare professionals require access to reliable and up-to-date information about the unavailability of a medicine in order that they can treat the patient in the best way possible. The significant patient impact because of the lack of medication, in terms of safety and management of their condition, will be researched. In addition the forced substitution to an alternative product or requirement to produce a medicine may increase the risk of error, stress and overall cost to the healthcare system. According to the largest pan-European survey of healthcare professionals yet conducted on the topic, the products mainly affected in the European hospital sector are antimicrobials and oncology products used for large populations. This Action will encourage systematic sharing of information and research about past, ongoing and future shortages of medicines and nutritional products. The Action aims to respond to clinical, financial and quality of life interests, to achieve analytical clarity on disruption causes, to simulate decision making in medicines production and trade, to highlight restrictive legal and economic frameworks, to disclose disincentives in the supply chain such as conflicts of interest or problematic cost-benefit ratios, and to reflect on best coping practices. 

Source

http://www.cost.eu/COST_Actions/ca/CA15105?

Posted by at
Labels:

Members area

Posted by at
Labels:

Management Committee

MC ChairProf Helena JENZER (CH)
MC Vice ChairDr Roberto FRONTINI (DE)

Working Group Leaders

WG LeaderProf Isabelle HUYS
WG LeaderProf Claude FARRUGIA
WG LeaderMs Jane NICHOLSON
WG LeaderMr Nenad MILJKOVIC
WG LeaderDr Tomasz BOCHENEK
■ Data registration in e-COST pending subject to online registration and nomination acceptance by nominee.

COST Participants

CountryMC Member
AustriaMs Gunda GITTLER
AustriaMs Martina JESKE
BelgiumProf Steven SIMOENS
BelgiumProf Isabelle HUYS
Bosnia and HerzegovinaMs Vesna VUJIC-ALEKSIC
Bosnia and HerzegovinaDr Lana NEZIC
CroatiaMs Darija KURUC POJE
CroatiaDr Suzana MIMICA MATANOVIĆ
CyprusDr Panagiotis PETROU
DenmarkDr Trine KART
DenmarkDr Marianne Hald CLEMMENSEN
FranceMr François HOUŸEZ
FranceDr Guillaume BÉRAUD
GermanyDr Roberto FRONTINI
GermanyMr Jürgen FUNKE
GreeceDr Leonidas TZIMIS
GreeceDr Mina GAGA
HungaryDr Botond LAKATOS
IrelandMs Joan PEPPARD
IrelandDr Vincent HARGADEN
IsraelProf David SCHWARTZ
IsraelMs Michal DAVIDESCU
ItalyDr Francesca VENTURINI
ItalyProf Roy CERQUETI
LatviaDr Inese SVIESTIŅA
LatviaMs Baiba ZIEMELE
LithuaniaDr Aurelija BURINSKIENE
MaltaProf Claude FARRUGIA
MaltaProf Lilian M. AZZOPARDI
MontenegroProf Bogdan ASANIN
MontenegroProf Natasa DUBORIJA-KOVACEVIC
NorwayDr Kristian SVENDSEN
PolandDr Tomasz BOCHENEK
PortugalProf João MIRANDA
RomaniaMr Paul ANDREIANU
RomaniaMr Ioan ANTOFIE
SerbiaMr Nenad MILJKOVIC
SerbiaMs Dragana RAJINAC
SloveniaMr Franci TRATAR
SpainDr Iñigo DE MIGUEL BERIAIN
SpainDr Elena ATIENZA-MACIAS
SwitzerlandProf Stefan GROESSER
Switzerland■ Dr Maurizio BATTISTINI
United KingdomMs Jane NICHOLSON
United KingdomMr Philip HOWARD
CountryMC Substitute
BelgiumMs Elfi DE WEERDT
CroatiaProf Iskra Alexandra NOLA
CroatiaProf Ana BOROVECKI
GreeceDr Eleni RINAKI
GreeceMs Despoina MAKRIDAKI
IrelandProf Sheila RYDER
IsraelMr Michael KHALEMSKY
LithuaniaProf Vida DAVIDAVICIENE
Malta■ Ms Miriam KERR
Montenegro■ Ms Željka BEŠOVIĆ
SerbiaMs Jasminka DRAGIC
SerbiaDr Veselin MITROVIC
SpainProf Jaime ESPIN BALBINO
SwitzerlandProf Pascal BONNABRY
SwitzerlandDr Priska VONBACH
SwitzerlandDr Enea MARTINELLI
United KingdomMr David PREECE
United KingdomMr Nick KAYE
Posted by at
Labels:

Countries

Action details

MoU037/15
CSO Approval date30/10/2015
Start of Action14/04/2016
End of Action13/04/2020

Participations

CountryDateStatus
Austria21/06/2016Confirmed
Belgium31/12/2015Confirmed
Bosnia and Herzegovina18/02/2016Confirmed
Croatia01/04/2016Confirmed
Cyprus28/04/2016Confirmed
Denmark07/01/2016Confirmed
France27/04/2016Confirmed
Germany24/11/2015Confirmed
Greece24/11/2015Confirmed
Hungary30/12/2016Confirmed
Ireland04/04/2016Confirmed
Israel02/02/2016Confirmed
Italy15/12/2016Confirmed
Latvia28/04/2016Confirmed
Lithuania31/03/2017Confirmed
Malta28/11/2015Confirmed
Montenegro08/03/2016Confirmed
Norway22/08/2017Confirmed
Poland03/03/2016Confirmed
Portugal26/04/2016Confirmed
Romania30/05/2016Confirmed
Serbia08/02/2016Confirmed
Slovenia15/11/2015Confirmed
Spain25/02/2016Confirmed
Switzerland21/01/2016Confirmed
United Kingdom16/11/2015Confirmed
Total: 26
Posted by at
Labels:

eCOST Action CA15105


eCOST (European Cooperation in Science and Technology) is the longest-running European framework supporting trans-national cooperation among researchers, engineers and scholars across Europe.

European Medicines Shortages Research Network - addressing supply problems to patients (Medicines Shortages) 

The problems created by supply shortages of medicines have been widely reported by healthcare professionals and patients over recent years, and acknowledged at the European level by the European Medicines Agency and European Commission. The cited causes are multifaceted ranging from production disruptions, natural disasters, discontinuations as well as difficulties created by various legal, trade and pricing frameworks. Healthcare professionals require access to reliable and up-to-date information about the unavailability of a medicine in order that they can treat the patient in the best way possible. The significant patient impact because of the lack of medication, in terms of safety and management of their condition, will be researched. In addition the forced substitution to an alternative product or requirement to produce a medicine may increase the risk of error, stress and overall cost to the healthcare system. According to the largest pan-European survey of healthcare professionals yet conducted on the topic, the products mainly affected in the European hospital sector are antimicrobials and oncology products used for large populations. This Action will encourage systematic sharing of information and research about past, ongoing and future shortages of medicines and nutritional products. The Action aims to respond to clinical, financial and quality of life interests, to achieve analytical clarity on disruption causes, to simulate decision making in medicines production and trade, to highlight restrictive legal and economic frameworks, to disclose disincentives in the supply chain such as conflicts of interest or problematic cost-benefit ratios, and to reflect on best coping practices. 

It is a unique means for them to jointly develop their own ideas and new initiatives across all fields in science and technology, including social sciences and humanities, through pan-European networking of nationally funded research activities. Based on a European intergovernmental framework for cooperation in science and technology, COST has been contributing - since its creation in 1971 - to closing the gap between science, policy makers and society throughout Europe and beyond. As a precursor of advanced multidisciplinary research, COST plays a very important role in building a European Research Area (ERA).

It anticipates and complements the activities of the EU Framework Programmes, constituting a “bridge” towards the scientific communities of COST Inclusiveness Target Countries. It also increases the mobility of researchers across Europe and fosters the establishment of scientific excellence.The problems created by supply shortages of medicines have been widely reported by healthcare professionals and patients over recent years, and acknowledged at the European level by the European Medicines Agency and European Commission. The cited causes are multifaceted ranging from production disruptions, natural disasters, discontinuations as well as difficulties created by various legal, trade and pricing frameworks.

Healthcare professionals require access to reliable and up-to-date information about the unavailability of a medicine in order that they can treat the patient in the best way possible. The significant patient impact because of the lack of medication, in terms of safety and management of their condition, will be researched. In addition the forced substitution to an alternative product or requirement to produce a medicine may increase the risk of error, stress and overall cost to the healthcare system. According to the largest pan-European survey of healthcare professionals yet conducted on the topic, the products mainly affected in the European hospital sector are antimicrobials and oncology products used for large populations.


This Action will encourage systematic sharing of information and research about past, ongoing and future shortages of medicines and nutritional products. The Action aims to respond to clinical, financial and quality of life interests, to achieve analytical clarity on disruption causes, to simulate decision making in medicines production and trade, to highlight restrictive legal and economic frameworks, to disclose disincentives in the supply chain such as conflicts of interest or problematic cost-benefit ratios, and to reflect on best coping practices.

Related links





  • COST brochure on ISSU
  • Horizon 2020
  • FET - Future and Emerging Technologies 
  • Why European Research?
  • European Research Area (ERA)
  • Research at the European Commission

    • Sources


    COST network

    http://www.cost.eu/COST_Actions/ca/CA15105 

    Posted by at
    Labels:
    Subscribe to: Posts (Atom)